Intervention of NF-κB activation pathway and its effects on malignant transformation of hepatocytes

Abstract

Abstract: The formation of hepatocellular carcinoma (HCC) is a multi-center, multi-etiology and multistage pathological progress with the chronic persistent infection of hepatitis viruses (HBV and HCV). The mutations of multigenes, oncogenes or anti-oncogenes at different stages are the molecular basics of hepatocarcinogenesis. NF-κB participates in initiation and progress of HCC, and the increasing of its expresssion may indicate the early cancerization of hepatocytes. Since NF-κB activation plays an important role in HCC development, the malignant transformation of hepatocytes may be interfered by inhibition of its activation. The approaches such as IKK-B gene knockout or expression of IκBαsuper repressor have been used to intervene the malignant transformation of hepatocytes to explore the molecular mechanisms and application values of HCC therapy.

Key words: NF-κB, hepatoma, signal pathway, activation pathway, intervention

CLC Number:

R735.7

YU Hong-bo, YAO Deng-fu. Intervention of NF-κB activation pathway and its effects on malignant transformation of hepatocytes[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2008, 13(2): 228-233.

References

[1] Raza SA, Clifford GM, Franceschi S. Worldwide variation in the relative importance of hepatitis B and hepatitic C viruses in hepatocellular carcinoma:a systematic review[J]. Br J Cancer, 2007, 96(7):1127-1134.
[2] Wang T, Wang Y, Wu MC, et al. Activating mechanism of transcriptor NF-kappaB regulated by hepatitis B virus X protein in hepatocellular carcinoma[J]. World J Gastroenterol, 2004, 10(3):356-360.
[3] Moynagh PN. The NF-kappaB pathway[J]. J Cell Sci, 2005, 118(Pt 20):4589-4592.
[4] Chan CF, Yau TO, Jin DY, et al. Evaluation of nuclear factor-kappaB, urokinase-type plasminogen activator, and HBx and their clinicopathological significance in hepatocellular carcinoma[J]. Clin Cancer Res, 2004, 10(12 Pt 1):4140-4149.
[5] Karin M. Nuclear factor-kappaB in cancer development and progression[J]. Nature, 2006, 441(7092 ):431-436.
[6] Tai DI, Tsai SL, Chang YH, et al. Constitutive activation of nuclear factor kappa B in hepatocellular carcinoma[J]. Cancer, 2000, 89(11):2274-2281.
[7] Su XQ, Wu XH, WuW, et al. Kinetic alterations of liver nuclear factor-kappa B and TNF-alpha expression at the early stage of HCC occurrence and clinical significances of their quantitative analysis[J]. J Gastroenterol Hepatol, 2006, 21(S2):A169.
[8] Pikarsky E, Porat RM, Stein I, et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer[J]. Nature, 2004, 431(7007):461-466.
[9] Li TJ, Jia LP, Gao XL, et al. Gene therapy that inhibits NF-kappaB results in apoptosis of human hepatocarcinoma by recombinant adenovirus[J]. World J Gastroenterol, 2006, 12(33):5287-5292.
[10] Qiao L, Yu J, Dent P, et al. NF-kappaB protects rat ARL-6 hepatocellular carcinoma cells against hydrogen peroxide-induced apoptosis[J]. Cancer Biol Ther, 2005, 4(11):1195-1202.
[11] Kim HS, Chang I, Kim JY, et al. Caspase-mediated p65 cleavage promotes TRAIL-induced apoptosis[J]. Cancer Res, 2005, 65(14):6111-6119.
[12] Cavin LG, Venkatraman M, Factor VM, et al. Regulation of alpha-fetoprotein by nuclear factor-kappaB protects hepatocytes from tumor necrosis factor-alpha cytotoxicity during fetal liver development and hepatic oncogenesis[J]. Cancer Res, 2004, 64(19):7030-7038.
[13] Maeda S, Kamata H, Luo JL, et al. IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis[J]. Cell, 2005, 121(7):977-990.
[14] Karin M, Greten FR. NF-kappa B:linking inflammation and immunity to cancer development and progression[J]. Nat Rev Immunol, 2005, 5(10):749-759.
[15] Sakurai T, Maeda S, Chang L, et al. Loss of hepatic NFkappa B activity enhances chemical hepatocarcinogenesis through sustained c-Jun N-terminal kinase 1 activation[J]. Proc Natl Acad Sci USA, 2006, 103(28):10544-10551.
[16] Park SG, Chung C, Kang H, et al. Up-regulation of cyclin D1 by HBx is mediated by NF-kappaB2 BCL3 complex through kappa B site of cyclin D1 promoter[J]. J Biol Chem, 2006, 281(42):31770-31777.
[17] Ogushi I, Iimuro Y, Seki E, et al. Nuclear factor kappa B decoy oligodeoxynucleotides prevent endotoxin-induced fatal liver failure in a murine model[J]. Hepatology, 2003, 38(2):335-344.
[18] Isomura I, Morita A. Regulation of NF-kappa B signaling by decoy oligodeoxynucleotides[J]. Microbiol Immunol, 2006, 50(8):559-563.
[19] Yan B, Chen XP, Zhang WG, et al. A double strand decoy DNA oligonucleotides for NF-κB-induced apoptosis and sensitization of hepatic cancer cells to chemotherapy[J]. Chin J Hepatobiliary Surg, 2004, 10:691-695.
[20] Zhang XY, Shimura S, Masuda T, et al. Antisense oligonucleotides to NF-kappaB improve survival in bleomy cininduced pneumopathy of the mouse[J]. Am J Respir Crit Care Med, 2000, 162(4 Pt 1):1561-1568.
[21] Murano M, Maemura K, Hirata I, et al. Therapeutic effect of intracolonically administered nuclear factor kappa B (p65) antisense oligonucleotide on mouse dextran sulphate sodium (DSS )-induced colitis[J]. Clin Exp Immunol, 2000, 120(1):51-58.
[22] Park SG, Ryu HM, Lim SO, et al. Interferon-gamma inhibits hepatitis B virus-induced NF-kappaB activation through nuclear localization of NF-kappaB-inducing kinase[J]. Gastroenterology, 2005, 128(7):2042-2053.
[23] Shigeno M, Nakao K, Ichikawa T, et al. Interferon-alpha sensitizes human hepatoma cells to TRAIL-induced apoptosis through DR5 upregulation and NF-kappa B inactivation[J]. Oncogene, 2003, 22(11):1653-1662.
[24] Wang J, Tokoro T, Higa S, et al. Anti-inflammatory effect of pitavastatin on NF-kappa B activated by TNF-alpha in hepatocellular carcinoma cells[J]. Biol Pharm Bull, 2006, 29(4):634-639.
[25] Chung TW, Moon SK, Chang YC, et al. Novel and therapeutic effect of caffeic acid and caffeic acid phenyl ester on hepatocarcinoma cells:complete regression of hepatoma growth and metastasis by dual mechanism[J]. FASEB J, 2004, 18(4):1670-1681.
[26] Ueno S, Aoki D, Kubo F, et al. Roxithromy cin inhibits constitutive activation of nuclear factor kappa B by diminishing oxidative stress in a rat model of hepatocellular carcinoma[J]. Clin Cancer Res, 2005, 11(5):5645-5650.
[27] Cabral F. Factors determining cellular mechanisms of resistance to antimitotic drugs[J]. Drug Resist Updat, 2001, 4(1):3-8.
[28] Lavon I, Pikarsky E, Gutkovich E, et al. Nuclear factorkappa B protects the liver against genotoxic stress and functions independently of p53[J]. Cancer Res, 2003, 63(1):25-30.
[29] Balkwill F. Tumor necrosis factor or tumor promoting factor?[J]. Cytokine Growth Factor Rev, 2002, 13(2):135-141.
[30] Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma[J]. Nat Genet, 2002, 31(4):339-346.
[31] Thorgeirsson SS, Lee JS, Grisham JW. Functional genomics of hepatocellular carcinoma[J]. Hepatology, 2006, 43(2 Suppl 1):S145-S150.
[32] Paul AG. NF-kB:A Novel Therapeutic Target for Cancer[J]. Eukaryon, 2005, 1(4 5):1-2.
[33] Lin A, Karin M. NF-kB in cancer:a marked target[J]. Semin Cancer Biol, 2003, 13(2):107-114.